Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio reports Q2 results (NASDAQ:BLTE)

Belite Bio (BLTE) Q2 press release: non-GAAP net loss widens to $21.6M; cash falls to $279.9M.

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant

Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease

Belite Bio recently announced that the U.S. FDA has accepted and granted Priority Review to its New Drug Application for tinlarebant to treat Stargardt Disease Type 1, with a PDUFA target action date set for February 12, 2027. If approved, tinlarebant would become the first FDA‑approved treatment for this rare inherited retinal disease, highlighting Belite Bio’s potential role in addressing a significant unmet medical need. We will now examine h…

FDA Accepts Belite Bio’s NDA for Tinlarebant in Stargardt Disease

Key Takeaways The FDA has accepted Belite Bio’s NDA for tinlarebant in Stargardt disease type 1 and granted Priority Review, with a PDUFA date of February 12, 2027 The phase 3 DRAGON trial showed a 35.7% reduction in the growth rate of atrophic retinal lesions with tinlarebant compared with placebo If approved, tinlarebant would become the first FDA-approved treatment for Stargardt disease type 1 The FDA has accepted Belite Bio’s new drug appl…